Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Terpos
E
E
Department of Clinical Therapeutics, University of Athens School of Medicine. Electronic address: eterpos@med.uoa.gr.
Christoulas
D
D
Department of Clinical Therapeutics, University of Athens School of Medicine.
Kokkoris
P
P
Departments of Endocrinology.
Anargyrou
K
K
Haematology, 251 General Air Force Hospital, Athens, Greece.
Gavriatopoulou
M
M
Department of Clinical Therapeutics, University of Athens School of Medicine.
Migkou
M
M
Department of Clinical Therapeutics, University of Athens School of Medicine.
Tsionos
K
K
Haematology, 251 General Air Force Hospital, Athens, Greece.
Dimopoulos
M A
MA
Department of Clinical Therapeutics, University of Athens School of Medicine.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004164:Diphosphonates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000188:drug therapy; D011719:Pyrazines / Q000008:administration & dosage; D015996:Survival Rate; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D011719:Pyrazines; D000069286:Bortezomib; D000077211:Zoledronic Acid; D003907:Dexamethasone